ERBB2 and carcinoma: Both Miglietta et al. [22] and Tarantino et al. [45] reported that HER2-low expression was highly unstable during disease progression, and there was a significant discordance (38% and 66%) in HER2-low expression between primary tumors and matched advanced stage tumors, with enrichment of HER2-low carcinomas in the advanced setting.